Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1732

Sort by

Sort Order Select

Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood (2019) 134 (23): 2036–2045.

https://doi.org/10.1182/blood.2019000069

Published: 2019

Includes: Supplemental data

Journal Articles

Dominant Role of αIIbβ3 in Platelet Interactions with Polymerizing Cross-Linked Fibrin

Claudia Lorena Buitrago, PhD, Barry S. Coller, MD, Hina Zafar

Blood (2019) 134 (Supplement_1): 1061.

https://doi.org/10.1182/blood-2019-122753

Published: 2019

Journal Articles

Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments

Elena Monzón Manzano, Raul Justo Sanz, Diana Hernández, Teresa Álvarez Roman, Ihosvany Fernandez-Bello, Mónica Martín, Larissa Valor, María Isabel Rivas Pollmar, Miguel A Canales, MD PhD, Victor Jimenez-Yuste, Nora Butta, PhD

Blood (2019) 134 (Supplement_1): 1089.

https://doi.org/10.1182/blood-2019-125772

Published: 2019

Journal Articles

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Fernanda S Seguro, MD, Felipe VR Maciel, MD, Guilherme O Lopes, Luciana Nardinelli, M.Sc, Vanderson Rocha, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1651.

https://doi.org/10.1182/blood-2019-125989

Published: 2019

Journal Articles

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Alessandra Iurlo, MD PhD, Mario Annunziata, MD, Francesco Albano, MD, Luigia Luciano, MD, Raffaele Spadano, MD, Anna Rita Scortechini, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD, Monia Lunghi, MD PhD, Alessandra Malato, MD PhD, Nicola Di Renzo, MD, Alfonso Piciocchi, Angela Pellegrino, MSc, Claudia Galimberti, Robin Foà, MD, Massimo Breccia, MD

Blood (2019) 134 (Supplement_1): 1652.

https://doi.org/10.1182/blood-2019-126098

Published: 2019

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

The Interaction of Tumor Cells and Myeloid-Derived Suppressor Cells in Chronic Myelogenous Leukemia

Hui Xu, Zunmin Zhu, Xiaojian Zhu, Na Shen, Shu Zhou, Yicheng Zhang

Blood (2019) 134 (Supplement_1): 1636.

https://doi.org/10.1182/blood-2019-125563

Published: 2019

Journal Articles

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

Ana Beatriz Pascoal Lopes, Eliana C Miranda, PhD, Valquíria Mariane Oliveira Póvoa, Bruna Rocha Vergílio, Graziele Cristina Pavan Furlin, Marcia Torresan Delamain, MD, Gislaine Borba Duarte, MD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Katia B Pagnano, MD PhD

Blood (2019) 134 (Supplement_1): 1637.

https://doi.org/10.1182/blood-2019-128265

Published: 2019

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Laurence Legros, MD PhD, Franck E Nicolini, MDPhD, Gabriel Etienne, MD PhD, Philippe Rousselot, MDPhD, Delphine Rea, MD, Stephane Giraudier, MD PhD, Agnès Guerci, MD PhD, Francoise Huguet, MD, Martine Gardembas, MD, Jean-Christophe Ianotto, MD PhD, Martine Escoffre-Barbe, MD, Valerie Coiteux, MD, Bruno Varet, MD, Stephane Morisset, BioStat, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 28.

https://doi.org/10.1182/blood-2019-123719

Published: 2019

Journal Articles

Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR

Elisa Diral, MD, Philipp Le Coutre, MD, Enrico Marco Gottardi, Chiara Elena, MD, Micaela Bergamaschi, MD, Sarit Assouline, MD, Eros Di Bona, MD, Jessica Petiti, PhD, Fabio Stagno, MD, Alessandra Iurlo, MD PhD, Dong-Wook Kim, Alessandra Pirola, MSc, Maria Luisa Bonanomi, Patrizia Crivori, PhD, Rocco Piazza, MD PhD, Carmen Fava, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 29.

https://doi.org/10.1182/blood-2019-125226

Published: 2019

Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 30.

https://doi.org/10.1182/blood-2019-124408

Published: 2019

Journal Articles

Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)

Haruko Shima, MD PhD, Akiko Kada, MPH, Akihiko Tanizawa, MD PhD, Yuki Yuza, MD PhD, Akihiro Watanabe, Masaki Ito, MD, Hideko Uryu, Katsuyoshi Koh, MD, Chihaya Imai, MD PhD, Nao Yoshida, MD PhD, Yuhki Koga, MD, Naoto Fujita, MD PhD, Akiko M Saito, MD PhD, Souichi Adachi, MD PhD, Eiichi Ishii, MD PhD, Hiroyuki Shimada, MD PhD

Blood (2019) 134 (Supplement_1): 25.

https://doi.org/10.1182/blood-2019-122623

Published: 2019

Journal Articles

A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts

Philippe Rousselot, MDPhD, Clémence Loiseau, MD, Marc Delord, PhD, Caroline Besson, MDPhD, Jean-Michel Cayuela, Marc Spentchian

Blood (2019) 134 (Supplement_1): 27.

https://doi.org/10.1182/blood-2019-129919

Published: 2019

Journal Articles

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Nabil K. Thalji, MD PhD, Prakash A Patel, MD, Rodney M. Camire, PhD

Blood (2019) 134 (Supplement_1): 3640.

https://doi.org/10.1182/blood-2019-125955

Published: 2019

Journal Articles

Identification of Optimal Thalassemia Screening Strategies for Migrant Populations in Thailand: A Mixed-Methods Approach

Julia Z. Xu, MD MSc, Meghan Foe, Wilaslak Tanongsaksakul, MD, Thidarat Suksangpleng, PhD, Supachai Ekwattanakit, PhDMD, Suchada Riolueang, MSc, Marilyn J. Telen, MD, Bonnie N. Kaiser, PhD, Vip Viprakasit, MD DPhil

Blood (2019) 134 (Supplement_1): 2112.

https://doi.org/10.1182/blood-2019-131805

Published: 2019

Journal Articles

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Pratibha Bhatia, MSc, BSc, Sumeet Prakash Mirgh, MBBS,MDDM, Vishvdeep Khushoo, MBBS,MDDM, Faran Naim, MD DNB, Ambar Garg, MD DNB, Rayaz Ahmed, MDDM, Narendra Agrawal, MD DM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 3500.

https://doi.org/10.1182/blood-2019-131763

Published: 2019

Journal Articles

Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia Associated with ALAS2 Missense Variants

Koya Ono, MD, Tohru Fujiwara, MD PhD, Kei Saito, MD PhD, Chie Suzuki, Noriyuki Takahashi, Koichi Onodera, MD PhD, Satoshi Ichikawa, MD PhD, Noriko Fukuhara, MD PhD, Yasushi Onishi, MD PhD, Hisayuki Yokoyama, MD PhD, Yukio Nakamura, MD PhD, Hideo Harigae, MD PhD

Blood (2019) 134 (Supplement_1): 3530.

https://doi.org/10.1182/blood-2019-124810

Published: 2019

Journal Articles

Rheological Effects of L-Glutamine in Patients with Sickle Cell Disease

Celeste K. Kanne, BA, Varun Reddy, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 3567.

https://doi.org/10.1182/blood-2019-128891

Published: 2019

NARROW

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Dominant Role of αIIbβ3 in Platelet Interactions with Polymerizing Cross-Linked Fibrin

Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

The Interaction of Tumor Cells and Myeloid-Derived Suppressor Cells in Chronic Myelogenous Leukemia

Pioglitazone Did Not Affect PPAR-Γ , STAT5 , HIF2α and CITED2 Gene Expression in Chronic Myeloid Leukemia Patients with Deep Molecular Response

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)

A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts

Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass

Identification of Optimal Thalassemia Screening Strategies for Migrant Populations in Thailand: A Mixed-Methods Approach

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia Associated with ALAS2 Missense Variants

Rheological Effects of L-Glutamine in Patients with Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only